FEB 0 2 1998

GP-1817/\$ LUD 5354.1-JEL/NDH

Response Under 37 C.F.R. § 1.116 Expedited Procedure Examining

hat this correspondence I hereby ce is being deposited with the United States Postal Services as first class mail in an envelope addressed to: Commissioner of Patents and Trademarks, Washington, D.C. 20231, on January 29 1998

FELFE & LYNCH

Pauline Smith

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s)

Yao-Tseng Chen et al.

Serial No.

08/560,024

Filed

February 20, 1996

For

MONOCLONAL ANTIBODIES WHICH BIND TO TUMOR REJECTION ANTIGEN PRECURSOR MAGE-1, RECOMBINANT MAGE-1, AND

Group/Art Unit 1817

MAGE-1 DERIVED IMMUNOGENIC PEPTIDES

Art Unit

1817

Examiner

A. Caputa

Hon. Commissioner of Patents and Trademarks Washington, D.C. 20231

AMENDMENT UNDER 37 C.F.R. §1.116

Sir:

This amendment is submitted in response to the Office Action of September 16 and the Advisory Action of January 13. A two month extension of time is required, and a request therefor, with fee, accompanies this amendment.

Please amend this application as follows: